PUBLIC RESEARCH DOSSIER
BCRX · Nasdaq百奥克里斯特制药
Manufacturing · Biological Products, (No Diagnostic Substances)完成交易日收盘US$8.57+3.94%行情日期 2026-11-03 · 非实时
公开资料页汇总百奥克里斯特制药（BCRX）的已发布行情、估值、风险、财务摘要与同业对比。行情截至2026-11-03，非实时；缺失值不按零处理。
股价走势
复权收盘价（美元）
2025-10-31 — 2026-11-03253 个交易日样本
BCRXUS$8.57
查看图表数据
| 日期 | BCRX |
|---|---|
| 2025-10-31 | 7.32 |
| 2025-11-03 | 6.86 |
| 2025-11-04 | 6.76 |
| 2025-11-05 | 7.17 |
| 2025-11-06 | 7.03 |
| 2025-11-07 | 7.09 |
| 2025-11-10 | 7.2 |
| 2025-11-11 | 7.23 |
| 2025-11-12 | 7.18 |
| 2025-11-13 | 6.9 |
| 2025-11-14 | 7.08 |
| 2025-11-17 | 7.03 |
| 2025-11-18 | 7 |
| 2025-11-19 | 6.93 |
| 2025-11-20 | 7.03 |
| 2025-11-21 | 6.97 |
| 2025-11-24 | 6.83 |
| 2025-11-25 | 6.85 |
| 2025-11-26 | 7.1 |
| 2025-11-28 | 7.18 |
| 2025-12-01 | 7.13 |
| 2025-12-02 | 7.16 |
| 2025-12-03 | 7.85 |
| 2025-12-04 | 7.83 |
| 2025-12-05 | 7.59 |
| 2025-12-08 | 7.7 |
| 2025-12-09 | 7.64 |
| 2025-12-10 | 7.66 |
| 2025-12-11 | 7.58 |
| 2025-12-12 | 7.57 |
| 2025-12-15 | 7.59 |
| 2025-12-16 | 7.47 |
| 2025-12-17 | 7.13 |
| 2025-12-18 | 7.29 |
| 2025-12-19 | 7.41 |
| 2025-12-22 | 7.61 |
| 2025-12-23 | 7.53 |
| 2025-12-24 | 7.7 |
| 2025-12-26 | 7.63 |
| 2025-12-29 | 7.71 |
| 2025-12-30 | 7.66 |
| 2025-12-31 | 7.8 |
| 2026-01-02 | 7.5 |
| 2026-01-05 | 7.41 |
| 2026-01-06 | 7.58 |
| 2026-01-07 | 7.92 |
| 2026-01-08 | 7.62 |
| 2026-01-09 | 7.4 |
| 2026-01-12 | 7.09 |
| 2026-01-13 | 6.75 |
| 2026-01-14 | 6.78 |
| 2026-01-15 | 7.17 |
| 2026-01-16 | 6.66 |
| 2026-01-20 | 6.67 |
| 2026-01-21 | 6.72 |
| 2026-01-22 | 6.75 |
| 2026-01-23 | 6.79 |
| 2026-01-26 | 6.86 |
| 2026-01-27 | 6.76 |
| 2026-01-28 | 6.66 |
| 2026-01-29 | 6.67 |
| 2026-01-30 | 6.58 |
| 2026-02-02 | 6.63 |
| 2026-02-03 | 6.7 |
| 2026-02-04 | 6.42 |
| 2026-02-05 | 6.24 |
| 2026-02-06 | 6.38 |
| 2026-02-09 | 6.3 |
| 2026-02-10 | 6.55 |
| 2026-02-11 | 6.84 |
| 2026-02-12 | 6.8 |
| 2026-02-13 | 6.76 |
| 2026-02-17 | 6.95 |
| 2026-02-18 | 7.26 |
| 2026-02-19 | 7.48 |
| 2026-02-20 | 7.45 |
| 2026-02-23 | 7.58 |
| 2026-02-24 | 7.61 |
| 2026-02-25 | 7.55 |
| 2026-02-26 | 7.9 |
| 2026-02-27 | 8.75 |
| 2026-03-02 | 8.63 |
| 2026-03-03 | 8.69 |
| 2026-03-04 | 8.57 |
| 2026-03-05 | 8.5 |
| 2026-03-06 | 8.48 |
| 2026-03-09 | 8.62 |
| 2026-03-10 | 8.75 |
| 2026-03-11 | 8.49 |
| 2026-03-12 | 8.38 |
| 2026-03-13 | 8.22 |
| 2026-03-16 | 9.3 |
| 2026-03-17 | 9.21 |
| 2026-03-18 | 9.16 |
| 2026-03-19 | 9.81 |
| 2026-03-20 | 9.7 |
| 2026-03-23 | 9.8 |
| 2026-03-24 | 9.66 |
| 2026-03-25 | 9.4 |
| 2026-03-26 | 9.56 |
| 2026-03-27 | 9.33 |
| 2026-03-30 | 9.45 |
| 2026-03-31 | 9.52 |
| 2026-04-01 | 9.38 |
| 2026-04-02 | 9.02 |
| 2026-04-06 | 9.47 |
| 2026-04-07 | 9.59 |
| 2026-04-08 | 9.78 |
| 2026-04-09 | 9.89 |
| 2026-04-10 | 9.56 |
| 2026-04-13 | 9.41 |
| 2026-04-14 | 9.67 |
| 2026-04-15 | 9.44 |
| 2026-04-16 | 9.52 |
| 2026-04-17 | 9.5 |
| 2026-04-20 | 9.19 |
| 2026-04-21 | 8.58 |
| 2026-04-22 | 9.01 |
| 2026-04-23 | 8.76 |
| 2026-04-24 | 8.94 |
| 2026-04-27 | 8.9 |
| 2026-04-28 | 8.86 |
| 2026-04-29 | 8.99 |
| 2026-04-30 | 9.16 |
| 2026-05-01 | 9.19 |
| 2026-05-04 | 9.2 |
| 2026-05-05 | 9.03 |
| 2026-05-06 | 8.83 |
| 2026-05-07 | 8.9 |
| 2026-05-08 | 8.62 |
| 2026-05-11 | 8.58 |
| 2026-05-12 | 8.8 |
| 2026-05-13 | 9.6 |
| 2026-05-14 | 9.57 |
| 2026-05-15 | 9.02 |
| 2026-05-18 | 8.97 |
| 2026-05-19 | 8.77 |
| 2026-05-20 | 8.74 |
| 2026-05-21 | 8.37 |
| 2026-05-22 | 8.29 |
| 2026-05-26 | 8.47 |
| 2026-05-27 | 9.12 |
| 2026-05-28 | 9.1 |
| 2026-05-29 | 8.91 |
| 2026-06-01 | 8.57 |
| 2026-06-02 | 8.34 |
| 2026-06-03 | 8.25 |
| 2026-06-04 | 8.47 |
| 2026-06-05 | 8.41 |
| 2026-06-08 | 8.43 |
| 2026-06-09 | 8.33 |
| 2026-06-10 | 8.19 |
| 2026-06-11 | 8.5 |
| 2026-06-12 | 8.7 |
| 2026-06-15 | 9.06 |
| 2026-06-16 | 8.92 |
| 2026-06-17 | 8.95 |
| 2026-06-18 | 8.99 |
| 2026-06-22 | 9.14 |
| 2026-06-23 | 9.31 |
| 2026-06-24 | 10 |
| 2026-06-25 | 9.9 |
| 2026-06-26 | 9.94 |
| 2026-06-29 | 9.55 |
| 2026-06-30 | 10 |
| 2026-07-01 | 9.65 |
| 2026-07-02 | 9.84 |
| 2026-07-06 | 10.17 |
| 2026-07-07 | 10.99 |
| 2026-07-08 | 11.11 |
| 2026-07-09 | 10.72 |
| 2026-07-10 | 10.45 |
| 2026-07-13 | 9.91 |
| 2026-07-14 | 9.74 |
| 2026-07-15 | 9.41 |
| 2026-07-16 | 9.11 |
| 2026-07-17 | 9.29 |
| 2026-07-20 | 9.11 |
| 2026-07-21 | 9.42 |
| 2026-07-22 | 9.51 |
| 2026-07-23 | 9.38 |
| 2026-07-24 | 9.34 |
| 2026-07-27 | 9.58 |
| 2026-07-28 | 9.74 |
| 2026-07-29 | 9.53 |
| 2026-07-30 | 9.24 |
| 2026-07-31 | 8.98 |
| 2026-08-03 | 8.81 |
| 2026-08-04 | 9.02 |
| 2026-08-05 | 9.07 |
| 2026-08-06 | 9.3 |
| 2026-08-07 | 9.38 |
| 2026-08-10 | 9.84 |
| 2026-08-11 | 10.34 |
| 2026-08-12 | 10.59 |
| 2026-08-13 | 9.81 |
| 2026-08-14 | 9.74 |
| 2026-08-17 | 9.94 |
| 2026-08-18 | 9.7 |
| 2026-08-19 | 10.07 |
| 2026-08-20 | 9.66 |
| 2026-08-21 | 9.55 |
| 2026-08-24 | 9.68 |
| 2026-08-25 | 9.83 |
| 2026-08-26 | 9.83 |
| 2026-08-27 | 9.87 |
| 2026-08-28 | 9.82 |
| 2026-08-31 | 9.7 |
| 2026-09-01 | 9.92 |
| 2026-09-02 | 10.17 |
| 2026-09-03 | 10.09 |
| 2026-09-04 | 9.96 |
| 2026-09-08 | 9.07 |
| 2026-09-09 | 8.81 |
| 2026-09-10 | 8.29 |
| 2026-09-11 | 8.12 |
| 2026-09-14 | 8.23 |
| 2026-09-15 | 8.16 |
| 2026-09-16 | 8.43 |
| 2026-09-17 | 8.7 |
| 2026-09-18 | 8.68 |
| 2026-09-21 | 8.76 |
| 2026-09-22 | 8.78 |
| 2026-09-23 | 8.57 |
| 2026-09-24 | 8.52 |
| 2026-09-25 | 8.59 |
| 2026-09-28 | 8.47 |
| 2026-09-29 | 8.27 |
| 2026-09-30 | 8.33 |
| 2026-10-01 | 8.12 |
| 2026-10-02 | 8.17 |
| 2026-10-05 | 8.1 |
| 2026-10-06 | 7.95 |
| 2026-10-07 | 8.4 |
| 2026-10-08 | 8.29 |
| 2026-10-09 | 8.55 |
| 2026-10-12 | 8.36 |
| 2026-10-13 | 8.07 |
| 2026-10-14 | 8.05 |
| 2026-10-15 | 8.02 |
| 2026-10-16 | 7.79 |
| 2026-10-19 | 8.07 |
| 2026-10-20 | 7.94 |
| 2026-10-21 | 7.75 |
| 2026-10-22 | 7.78 |
| 2026-10-23 | 7.65 |
| 2026-10-26 | 7.88 |
| 2026-10-27 | 8.1 |
| 2026-10-28 | 8.37 |
| 2026-10-29 | 8.52 |
| 2026-10-30 | 8.47 |
| 2026-11-02 | 8.25 |
| 2026-11-03 | 8.57 |
1、3、6、12个月分别按21、63、126、252个交易日取区间；缺失日期不从区间外补齐。
使用已有每日复权收盘样本，非实时行情；图中价格可能与未复权收盘报价不同。
01 · MARKET FRAME
行情、估值与风险
基于已完成交易日和已发布财务资料
区间涨跌幅
区间涨跌幅使用复权收盘价；估值和风险指标缺失时显示为—，不按零处理。
02 · FINANCIAL TRACE
财务摘要
公开页仅显示最近3个已校验报告期
年度财务走势
百万美元 · 年度报告期
所选指标暂无已校验的年度资料，缺失值不按零处理。
| 指标 | 2026-07-31 | 2026-06-30 | 2025-12-31 | 2025-07-31 | 2025-06-30 | 2024-12-31 | 2024-07-31 | 2024-06-30 | 2023-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| 营收 | — | — | — | — | — | — | — | — | — |
| 净利润 | — | — | 263.9 | — | — | -88.9 | — | — | -226.5 |
| 自由现金流 | — | — | 344.9 | — | — | -53.1 | — | — | -97.3 |
| 股份数 | 255.5 | — | — | 209.9 | — | — | 206.9 | — | — |
| 债务 | — | — | — | — | — | — | — | — | — |
| 总资产 | — | 557.9 | — | — | 457.2 | — | — | 472.4 | — |
金额及股份数均以百万为单位。缺失或待核验数据不按零处理。
03 · PEER SET
同业对比
同一细分行业中市值最接近的公司
| 公司 | 市值 | 近250日涨跌幅 | 市盈率 | 距52周高点 | 波动率 |
|---|---|---|---|---|---|
| VCELVericel Corp | US$2.1B | +13.4% | 86.9× | -14.9% | +41.2% |
| COAGHemab Therapeutics Holdings, Inc. | US$2B | — | — | — | — |
| REPL瑞普利缪恩 | US$2B | +130.2% | — | +6% | +187.1% |
| ADMA艾德玛生物 | US$2.5B | -24.1% | 14.7× | -45.5% | +54.2% |
同业由已覆盖公司的行业分类和市值接近度确定，仅用于横向研究；缺失数据不按零处理。